Dr. Wagner

John L. Wagner, MD

Contact Dr. Wagner

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization
  2. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  3. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  4. Investigation of a Clostridium difficile cluster by multilocus sequence typing in a bone marrow transplant unit
  5. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation
  6. Canine immunogenetics
  7. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  8. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  9. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  10. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  11. Port site metastasis of B-cell lymphoma: A first occurrence or an underreported complication?
  12. Sequence of the canine major histocompatibility complex region containing non-classical class I genes
  13. Cytoprotection in acute myelogenous leukemia (AML) therapy
  14. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  15. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  16. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
  17. Molecular Organization of the Canine Major Histocompatibility Complex
  18. Cellular, serological, and molecular polymorphism of the class I and class II loci of the canine major histocompatibility complex
  19. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches
  20. Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee